{
    "clinical_study": {
        "@rank": "112776", 
        "arm_group": {
            "arm_group_label": "Hyperbaric Oxygen Treatment", 
            "arm_group_type": "Experimental", 
            "description": "Administration of hyperbaric oxygen the morning of UCB transplant."
        }, 
        "brief_summary": {
            "textblock": "By doing this study, researchers hope to learn the following:\n\n        -  If providing hyperbaric oxygen (HBO) therapy prior to an umbilical cord blood (UBC)\n           transplant will help to improve the homing process\n\n        -  The safety of HBO administration in the setting of the UBC transplant\n\n        -  The effects of HBO therapy on the engraftment process"
        }, 
        "brief_title": "Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Myeloid Leukemia", 
            "Acute Lymphoblastic Leukemia", 
            "Myelodysplastic Syndrome (MDS)", 
            "Hodgkins Lymphoma", 
            "Non-Hodgkins Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hodgkin Disease", 
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "Research has suggested that high levels of erythropoietin (EPO) decreases the ability of\n      infused umbilical cord stem cells to home to the bone marrow.  The investigators will\n      investigate the use of hyperbaric oxygen (HBO) therapy to decrease the plasma concentrations\n      of EPO prior to UBC transplant and evaluate the resulting impact on UBC homing."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Voluntary written informed consent\n\n          -  Subjects must be >/= 18 yrs and </= 70 yrs for non-myeloablative transplant\n\n          -  Subjects must be >/= 18 yrs and </= 55 yrs for myeloablative transplant\n\n          -  Subjects with Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL),\n             Myelodysplastic Syndrome (MDS), Hodgkin's Lymphoma (HL) and Non-Hodgkin's Lymphoma\n             (NHL) who are considered for UCB transplant\n\n          -  Use of approved form of contraception\n\n          -  Karnofsky performance status of >/= 70%\n\n          -  Adequate hepatic, renal, pulmonary and cardiac function.  Criteria include:\n\n          -  ALT (alanine aminotransferase), AST (aspartate aminotransferase: < 4x IULN\n             (institutional upper limit of normal)\n\n          -  Total bilirubin </= 2 mg/dL\n\n          -  Serum creatinine < 2.0 mg/dL\n\n          -  Left ventricular ejection fraction >/= 45%\n\n          -  FEV1 (forced expiratory volume), FVC (forced vital capacity) and DLCD (diffusing\n             capacity of lung for carbon monoxide) >/= 50% of predicted value (corrected to serum\n             hemoglobin)\n\n        Exclusion Criteria:\n\n          -  Pregnancy or breast feeding\n\n          -  Severe chronic obstructive pulmonary disease requiring oxygen supplementation\n\n          -  History of spontaneous pneumothorax\n\n          -  History of seizures\n\n          -  Claustrophobia\n\n          -  Asthma\n\n          -  Uncontrolled viral or bacterial infection at the time of enrollment\n\n          -  Active or recent (prior 6 months) invasive fungal infection without interdisciplinary\n             consult and approval"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02099266", 
            "org_study_id": "BMT-2011-08-01"
        }, 
        "intervention": {
            "arm_group_label": "Hyperbaric Oxygen Treatment", 
            "description": "Hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours", 
            "intervention_name": "Administration of hyperbaric oxygen", 
            "intervention_type": "Device", 
            "other_name": "Monoplace Hyperbaric Chamber Model 3200 and 3200R"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Umbilical Cord Blood (UCB) Stem Cell Transplant", 
            "Hyperbaric oxygen", 
            "Leukemia", 
            "Lymphoma", 
            "MDS"
        ], 
        "lastchanged_date": "March 25, 2014", 
        "location": {
            "contact": {
                "email": "oaljitawi@Kumc.edu", 
                "last_name": "Omar Aljitawi, MD", 
                "phone": "913-588-6029"
            }, 
            "contact_backup": {
                "email": "kdaniels2@kumc.edu", 
                "last_name": "Kelly Daniels", 
                "phone": "913-945-6591"
            }, 
            "facility": {
                "address": {
                    "city": "Kansas City", 
                    "country": "United States", 
                    "state": "Kansas", 
                    "zip": "66160"
                }, 
                "name": "University of Kansas Medical Center"
            }, 
            "investigator": {
                "last_name": "Omar Aljitawi, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pilot Study to Determine the Safety and Efficacy of Using Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment", 
        "other_outcome": [
            {
                "description": "Determine if inflammatory cytokine and EPO levels are dropping after the HBO treatment", 
                "measure": "To explore the effects of HBO therapy on inflammatory cytokines and EPO levels", 
                "safety_issue": "No", 
                "time_frame": "Blood sample collection Pre-HBO (Day 0), 6hrs, 8hrs, 24hrs, 48hrs post HBO."
            }, 
            {
                "description": "Erythropoietin blood levels will be correlated to the daily neutrophil counts to assess any relationship between EPO levels and subsequent engraftment and neutrophil recovery.", 
                "measure": "Determine the correlation between change in EPO levels and time to neutrophil recovery and engraftment.", 
                "safety_issue": "No", 
                "time_frame": "EPO measurements:  Pre-HBO (Day 0), 6hrs, 8hrs, 24hrs, 48hrs post HBO."
            }
        ], 
        "overall_contact": {
            "email": "oaljitawi@kumc.edu", 
            "last_name": "Omar Aljitawi, MD", 
            "phone": "913-588-6029"
        }, 
        "overall_contact_backup": {
            "email": "kdaniels2@kumc.edu", 
            "last_name": "Kelly Daniels", 
            "phone": "913-945-6591"
        }, 
        "overall_official": {
            "affiliation": "University of Kansas", 
            "last_name": "Omar Aljitawi, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Treatment limiting toxicities are defined as the occurrence of any of the following complications within 24hrs of treatment:  pneumothorax, death, irreversible grade III or any grade IV toxicity that is determined by the treating physician to be related to HBO therapy.", 
            "measure": "Safety of HBO administration in the setting of UCB stem cell transplantation", 
            "safety_issue": "Yes", 
            "time_frame": "Toxicity assessment with 24hrs of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02099266"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Subjects will be followed daily until neutrophil recovery, defined as three consecutive days of achieving a neutrophil level >/= 500 u/L.", 
                "measure": "Determine the effects of HBO therapy on neutrophil count recovery.", 
                "safety_issue": "No", 
                "time_frame": "Daily measurement of neutrophil counts up to 90 days post transplant."
            }, 
            {
                "description": "The degree of engraftment will be determined through bone marrow chimerism assessments at either 21 or 28 days.  Partial engraftment is defined as marrow reconstitution of 10-90% or donor cells and complete engraftment is defined as greater that 90% of donor cells.", 
                "measure": "Determine the effects of HBO therapy on engraftment", 
                "safety_issue": "No", 
                "time_frame": "Bone marrow chimerism testing at Day 21 or Day 28"
            }
        ], 
        "source": "University of Kansas", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Kansas", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}